Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CABERGOLINE vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Treatment of hyperprolactinemic disorders (e.g., amenorrhea, galactorrhea, infertility),Prolactin-secreting pituitary adenomas (microadenomas and macroadenomas)
Management of mild to moderate pain,Reduction of fever
0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life is 63-68 hours in healthy subjects, allowing for once- or twice-weekly dosing. In hepatic impairment, half-life may be prolonged.
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Extensively metabolized in the liver, primarily by hydrolysis and minor CYP3A4 involvement.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Approximately 60-70% of the dose is excreted in feces (primarily as unchanged drug and metabolites), with about 20-30% excreted renally (mostly as metabolites).
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
40-42% bound to plasma proteins, primarily albumin.
10-25% bound to albumin at therapeutic concentrations.
Approximately 100-150 L/kg, indicating extensive tissue distribution; Vd is large (≥100 L/kg) due to high lipophilicity and tissue binding.
0.8-1.0 L/kg; suggests distribution into total body water.
Oral bioavailability is about 40-45% (range 30-60%) due to first-pass metabolism. No parenteral formulations are commonly used.
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No dosage adjustment recommended for mild to moderate renal impairment (Cr Cl >10 m L/min); avoid use in severe renal impairment (Cr Cl <10 m L/min) due to lack of data.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh class C) as elimination may be reduced.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not FDA approved for pediatric use; limited data: 0.025-0.05 mg/kg once weekly, titrated cautiously based on prolactin levels; maximum 0.1 mg/kg weekly.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific adjustment recommended; start at lower end of dosing range (0.25 mg twice weekly) due to potential for increased sensitivity and age-related decline in renal function.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
Cabergoline is associated with an increased risk of cardiac valve regurgitation, especially at high doses used for Parkinson's disease. The risk appears lower at doses used for hyperprolactinemia, but caution is advised.
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Cardiac valvulopathy: monitor with echocardiography before and during therapy,Pleural, pericardial, and retroperitoneal fibrosis,Postural hypotension,Impulse control disorders (e.g., pathological gambling, hypersexuality),Remission of prolactinomas may reduce pituitary function
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Hypersensitivity to cabergoline or ergot derivatives,Uncontrolled hypertension,History of cardiac valvular disease,Pregnancy: use only if clearly needed (category B)
Hypersensitivity to acetaminophen or any component of the formulation
Avoid high-fat meals that may increase absorption variability. No specific food restrictions, but take consistently with meals to maintain stable levels. Grapefruit juice may theoretically increase cabergoline exposure (CYP3A4 inhibition); avoid excessive consumption.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasoconstriction may cause fetal hypoxia; use only if benefit outweighs risk. Second and third trimesters: risk of postpartum hemorrhage and uterine atony if used for lactation suppression; avoid in pregnancy due to potential for fetal harm from dopamine agonist effects.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
Cabergoline suppresses lactation; contraindicated in breastfeeding women because it reduces milk production. If used, discontinue breastfeeding or avoid drug. M/P ratio not established; drug is excreted in rat milk, unknown in humans.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No standard dose adjustment recommended; avoid use during pregnancy unless absolutely necessary (e.g., prolactinoma). Pregnancy may alter cabergoline pharmacokinetics (increased volume of distribution, decreased clearance) but specific dose modifications are not established. If used, monitor prolactin levels and clinical response.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Start with 0.25 mg twice weekly, titrate by 0.25 mg every 2-4 weeks based on prolactin levels and tolerability. Maximum dose typically 1 mg twice weekly. May cause orthostatic hypotension; caution when rising from supine position. Use lowest effective dose to minimize risk of valvulopathy, especially with cumulative doses >2 mg/day. Discontinue if signs of cardiac fibrosis. Monitor for impulse control disorders (e.g., hypersexuality, gambling). Avoid in patients with uncontrolled hypertension or pre-existing cardiac valvular disease.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take with food to reduce gastrointestinal upset.,Avoid alcohol as it may increase side effects like dizziness or nausea.,Rise slowly from sitting or lying positions to prevent fainting.,Report any new shortness of breath, swelling, or chest pain immediately.,Notify your doctor if you experience unusual urges (gambling, sex, spending).,Do not drive or operate machinery if you feel dizzy or drowsy.,Take exactly as prescribed; do not double the dose if missed.,Store at room temperature away from moisture and heat.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
"Trazodone, a serotonin antagonist and reuptake inhibitor, and cabergoline, a dopamine D2 receptor agonist, exhibit opposing effects on the dopaminergic and serotonergic systems, potentially leading to reduced therapeutic efficacy and increased risk of adverse effects such as serotonin syndrome or dopaminergic toxicity. The combination may precipitate hypertensive crises or cardiac valvulopathy due to additive effects on 5-HT2B receptor activation by cabergoline, while trazodone's blockade of serotonin reuptake can exacerbate serotonin excess. Clinical outcomes include unpredictable blood pressure fluctuations, neuropsychiatric disturbances, and rare but serious cardiovascular events."
"Cabergoline, a dopamine D2 receptor agonist used for hyperprolactinemia, may inhibit the metabolism of methylene blue, a monoamine oxidase inhibitor (MAOI) used for methemoglobinemia. This interaction can lead to elevated methylene blue levels, increasing the risk of serotonin syndrome, characterized by hyperthermia, agitation, and neuromuscular abnormalities. Clinically, patients may present with confusion, tachycardia, and hypertension, necessitating cautious use."
"Cabergoline, a dopaminergic ergot derivative, acts as a vasoconstrictor via agonism of serotonin 5-HT2B and dopamine D1 receptors in vascular smooth muscle. Nadolol, a non-selective beta-blocker, inhibits beta-2 adrenergic receptor-mediated vasodilation, leaving alpha-adrenergic vasoconstriction unopposed. The combined vasoconstrictive effects can lead to additive peripheral and coronary vasoconstriction, potentially causing severe hypertension, myocardial ischemia, or Raynaud's phenomenon."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CABERGOLINE vs INJECTAPAP, answered by our medical review team.
CABERGOLINE is a Dopamine Agonist that works by Cabergoline is a long-acting dopamine D2 receptor agonist that inhibits prolactin secretion by the anterior pituitary gland.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CABERGOLINE and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CABERGOLINE is: 0.25 mg orally twice weekly, up to 1 mg twice weekly; for hyperprolactinemia, initial 0.25 mg twice weekly, titrate by 0.25 mg every 4 weeks based on prolactin levels.. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CABERGOLINE and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CABERGOLINE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; limited human data. In first trimester, theoretical risk of ergot alkaloid-induced uteroplacental vasocon. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.